Best Semaglutide Providers in 2026 — Ranked & Reviewed
Looking for a trusted semaglutide provider? We independently scored every major telehealth clinic offering compounded and brand-name semaglutide in 2026. Each provider is evaluated on pricing transparency, clinical oversight, shipping, and user experience — so you can find a legitimate, affordable option without falling for sketchy ads.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support. Compounded GLP-1s from licensed 503A and 503B pharmacies are legal under federal compounding law[2], with additional tolerances historically allowed while semaglutide and tirzepatide were on the FDA Drug Shortage List[3].
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Enhance MD
Verified partnerBest for: lab-monitored compounded GLP-1 with mandatory video visit
Enhance MD pairs compounded semaglutide and tirzepatide with mandatory baseline metabolic labs at Quest Diagnostics and a synchronous video visit with a board-certified clinician — a more rigorous onboarding than the async-only compounded GLP-1 model most telehealth providers use. Three tiers (Core semaglutide, Advanced tirzepatide, Elite combined) plus aggressive intro pricing ($49 first month on Core).
Score Breakdown
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Low first-month intro pricing: $49 Core, $99 Advanced, $189 Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro pricing resets to full tier rate after 30 days — the $49/$99/$189 figures aren't ongoing cost
Embody
Verified partnerBest for: lowest first-month entry pricing on compounded GLP-1s
Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
TrimRx
Verified partnerBest for: best overall value
TrimRx is a telehealth weight-loss program offering compounded semaglutide prescribed by licensed US medical providers after an online medical-history review, with medication shipped monthly and free shipping. It leans on price stability and dose continuity — "switch and keep your current dose, no price hikes" — and needs no insurance (cash-pay, tiered monthly pricing plus multi-month bundles). Compounded GLP-1s are not FDA-approved. The compounding pharmacy and state list are not published, specifics are gated behind the intake quiz, and no LegitScript certification is shown.
Score Breakdown
Pros
- ✓Compounded semaglutide prescribed by licensed US medical providers after an online medical-history review
- ✓Free shipping with medication delivered to your door monthly — can start as soon as the next day
- ✓Price-stability positioning: "switch and keep your current dose," with no advertised mid-program price hikes
- ✓Tiered monthly pricing from ~$179/mo plus discounted multi-month bundles; no insurance required (cash-pay)
- ✓24/7 patient portal for support; publishes HIPAA, privacy, SMS, and terms policies
Cons
- ✗Async, questionnaire-based intake — no mandatory video visit with a clinician before prescribing
- ✗Compounded semaglutide is not FDA-approved (the site discloses this) — it is not brand Wegovy or Ozempic
- ✗Only compounded semaglutide injections are advertised — tirzepatide and oral options are not publicly listed
- ✗Compounding pharmacy partner is not named, and the state-availability list is not published
- ✗Pricing tiers and program details are gated behind the intake quiz; no LegitScript certification displayed
Telos Rx
Verified partnerBest for: Needle-free and microdosed compounded GLP-1 options with lab-monitored care
Telos Rx is a compounded telehealth platform (Superior Health Solutions LLC) offering GLP-1 weight loss alongside longevity, recovery, and sexual-health peptides. Its GLP-1 line includes compounded semaglutide and tirzepatide injections plus needle-free sublingual and microdosed tirzepatide, with provider dose adjustments, lab monitoring, free discreet shipping, FSA/HSA, and cancel-anytime. Headline prices are first-month intro rates (from $49); ongoing cost is higher. Compounded meds are not FDA-approved; pharmacy and states unpublished; no LegitScript shown.
Score Breakdown
Pros
- ✓Multiple GLP-1 modalities: compounded semaglutide and tirzepatide injections plus needle-free sublingual and microdosed tirzepatide
- ✓Provider-led dose adjustments and lab monitoring as your protocol changes
- ✓Free discreet, temperature-controlled shipping (no Telos branding on the outside)
- ✓FSA/HSA eligible and cancel anytime in one click
- ✓Trustpilot rating of 4.9; full compliance suite published (Privacy, Terms, HIPAA, Shipping & returns)
- ✓Integrated care team spanning weight loss, longevity, recovery, and sexual health (peptide-led)
Cons
- ✗Headline pricing is 'first month low as' intro pricing (semaglutide $49, tirzepatide $99) — ongoing monthly cost is higher and shown during intake
- ✗Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- ✗Compounding pharmacy partner is not named
- ✗State-availability list is not published
- ✗No LegitScript certification displayed
Strut Health
Verified partnerBest for: oral-lozenge compounded GLP-1 access
Strut Health offers LegitScript + ACHC-accredited compounded semaglutide and tirzepatide in both injectable and oral lozenge formats, shipping to 49 states. Board-certified US physicians handle prescribing with free unlimited follow-up messaging, but eligibility is gated behind a 'medical necessity' clinician determination that isn't publicly defined.
Score Breakdown
Pros
- ✓Both LegitScript and ACHC accredited — pharmacy oversight most compounded GLP-1 providers don't carry
- ✓Oral lozenge option for semaglutide ($99/mo) and tirzepatide ($199/mo) — an injection-free alternative
- ✓Auto-refill pricing saves 13–21% vs one-off orders
- ✓Free unlimited follow-up messaging with board-certified US physicians
- ✓Ships to 49 states (only Arkansas excluded)
Cons
- ✗Requires a "medical necessity" review, but the criteria aren't published — you can't self-screen before paying for a consult
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Pharmacy partners aren't named — you can't verify the compounding source
- ✗No insurance accepted — cash pay only
- ✗Phone consultation requirement varies by state
Related Rankings
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Wegovy · Drugs and brands
- Ozempic · Drugs and brands
- Rybelsus · Drugs and brands
- Semaglutide · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.